Compare IQV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | CRDO |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | Cayman Islands |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 50.7B |
| IPO Year | 2013 | 2022 |
| Metric | IQV | CRDO |
|---|---|---|
| Price | $278.80 | $148.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 20 |
| Target Price | ★ $299.11 | $279.09 |
| AVG Volume (30 Days) | 1.1M | ★ 6.7M |
| Earning Date | 10-27-2026 | 11-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.67 | ★ 765.52 |
| EPS | ★ 1.61 | 0.67 |
| Revenue | ★ $9,739,000,000.00 | $1,335,116,000.00 |
| Revenue This Year | $6.78 | $87.41 |
| Revenue Next Year | $6.06 | $54.80 |
| P/E Ratio | ★ $171.99 | $244.33 |
| Revenue Growth | 41.60 | ★ 205.68 |
| 52 Week Low | $154.50 | $86.49 |
| 52 Week High | $282.98 | $308.67 |
| Indicator | IQV | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 33.04 |
| Support Level | $252.55 | $91.09 |
| Resistance Level | N/A | $164.80 |
| Average True Range (ATR) | 8.06 | 14.01 |
| MACD | 1.35 | -4.69 |
| Stochastic Oscillator | 85.22 | 7.41 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.